Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators

Luminal breast cancer subtypes respond poorly to endocrine and trastuzumab treatments due to cellular heterogeneity arising from the phenotype transitions, accounted for mainly by the loss of receptor expression. The origins of basal-like and human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer subtypes have been attributed to genetic and protein modifications in stem-like cells and luminal progenitor cell populations, respectively. The post-transcriptional regulation of protein expression is known to be influenced by microRNAs (miRNAs) that are deemed to be master regulators of several biological processes in breast tumorigenesis and progression. Our objective was to identify the fractions of luminal breast cancer cells that share stemness potentials and marker profiles and to elucidate the molecular regulatory mechanism that drives transitions between fractions, leading to receptor discordances. Established breast cancer cell lines of all prominent subtypes were screened for the expression of putative cancer stem cell (CSC) markers and drug transporter proteins using a side population (SP) assay. Flow-cytometry-sorted fractions of luminal cancer cells implanted in immunocompromised mice generated a pre-clinical estrogen receptor alpha (ERα+) animal model with multiple tumorigenic fractions displaying differential expression of drug transporters and hormone receptors. Despite an abundance of estrogen receptor 1 (ESR1) gene transcripts, few fractions transitioned to the triple-negative breast cancer (TNBC) phenotype with a visible loss of ER protein expression and a distinct microRNA expression profile that is reportedly enriched in breast CSCs. The translation of this study has the potential to provide novel therapeutic miRNA-based targets to counter the dreaded subtype transitions and the failure of antihormonal therapies in the luminal breast cancer subtype.

[1]  S. Mader,et al.  Positive Regulation of Estrogen Receptor Alpha in Breast Tumorigenesis , 2021, Cells.

[2]  N. Miller,et al.  MicroRNAs in Molecular Classification and Pathogenesis of Breast Tumors , 2021, Cancers.

[3]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[4]  A. Jemal,et al.  Cancer Statistics, 2021 , 2021, CA: a cancer journal for clinicians.

[5]  Lang Li,et al.  Breast Cancer Stem Cells: Biomarkers, Identification and Isolation Methods, Regulating Mechanisms, Cellular Origin, and Beyond , 2020, Cancers.

[6]  F. Belluti,et al.  Reconsidering Aromatase for Breast Cancer Treatment: New Roles for an Old Target , 2020, Molecules.

[7]  R. M. Pillai,et al.  Transitional dynamics of cancer stem cells in invasion and metastasis , 2020, Translational oncology.

[8]  H. Ford,et al.  Cellular Plasticity in Breast Cancer Progression and Therapy , 2020, Frontiers in Molecular Biosciences.

[9]  M. Pan,et al.  The CDK6-c-Jun-Sp1-MMP-2 axis as a biomarker and therapeutic target for triple-negative breast cancer. , 2020, American journal of cancer research.

[10]  K. Wei,et al.  miR-29b-3p promotes progression of MDA-MB-231 triple-negative breast cancer cells through downregulating TRAF3 , 2019, Biological Research.

[11]  J. Freedman,et al.  Circulating microRNAs miR-331 and miR-195 differentiate local luminal a from metastatic breast cancer , 2019, BMC Cancer.

[12]  Changying Guo,et al.  miR-29a contributes to breast cancer cells epithelial–mesenchymal transition, migration, and invasion via down-regulating histone H4K20 trimethylation through directly targeting SUV420H2 , 2019, Cell Death & Disease.

[13]  Xiaohe Yang,et al.  microRNA Regulation in Estrogen Receptor-Positive Breast Cancer and Endocrine Therapy , 2018, Biological procedures online.

[14]  A. Friedl,et al.  Antiestrogen Therapy Increases Plasticity and Cancer Stemness of Prolactin-Induced ERα+ Mammary Carcinomas. , 2018, Cancer research.

[15]  T. S. Santhosh Kumar,et al.  Analysis of MicroRNA-mRNA Interactions in Stem Cell-Enriched Fraction of Oral Squamous Cell Carcinoma. , 2018, Oncology research.

[16]  Xiaofeng Dai,et al.  Breast Cancer Cell Line Classification and Its Relevance with Breast Tumor Subtyping , 2017, Journal of Cancer.

[17]  A. Korlimarla,et al.  Dissecting the Biological Heterogeneity within Hormone Receptor Positive HER2 Negative Breast Cancer by Gene Expression Markers Identifies Indolent Tumors within Late Stage Disease , 2017, Translational oncology.

[18]  J. Remacle,et al.  Data on alteration of hormone and growth factor receptor profiles over progressive passages of breast cancer cell lines representing different clinical subtypes , 2016, Data in brief.

[19]  N. Saini,et al.  MicroRNA-195 inhibits proliferation, invasion and metastasis in breast cancer cells by targeting FASN, HMGCR, ACACA and CYP27B1 , 2015, Scientific Reports.

[20]  A. Puisieux,et al.  ABCG2, a novel antigen to sort luminal progenitors of BRCA1- breast cancer cells , 2014, Molecular Cancer.

[21]  S. Baylin,et al.  Cancer epigenetics: tumor heterogeneity, plasticity of stem-like states, and drug resistance. , 2014, Molecular cell.

[22]  J. Remacle,et al.  Separate quality-control measures are necessary for estimation of RNA and methylated DNA from formalin-fixed, paraffin-embedded specimens by quantitative PCR. , 2014, The Journal of molecular diagnostics : JMD.

[23]  N. Dendukuri,et al.  A Majority of Low (1-10%) ER Positive Breast Cancers Behave Like Hormone Receptor Negative Tumors , 2014, Journal of Cancer.

[24]  W. Gallagher,et al.  miRNA dysregulation in breast cancer. , 2013, Cancer research.

[25]  T. S. Santhosh Kumar,et al.  Multiple drug resistant, tumorigenic stem-like cells in oral cancer. , 2013, Cancer letters.

[26]  Ugo Ala,et al.  MicroRNA-Antagonism Regulates Breast Cancer Stemness and Metastasis via TET-Family-Dependent Chromatin Remodeling , 2013, Cell.

[27]  F. Heitz,et al.  Differences in the Receptor Status between Primary and Recurrent Breast Cancer - The Frequency of and the Reasons for Discordance , 2013, Oncology.

[28]  Qun Zhou,et al.  Estrogen Receptor α Signaling Regulates Breast Tumor-initiating Cells by Down-regulating miR-140 Which Targets the Transcription Factor SOX2* , 2012, The Journal of Biological Chemistry.

[29]  J. Reis-Filho,et al.  Epithelial and Mesenchymal Subpopulations Within Normal Basal Breast Cell Lines Exhibit Distinct Stem Cell/Progenitor Properties , 2012, Stem cells.

[30]  Craig D. Shriver,et al.  Effect of ASCO/CAP Guidelines for Determining ER Status on Molecular Subtype , 2012, Annals of Surgical Oncology.

[31]  Alysha K Croker,et al.  Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells , 2012, Breast Cancer Research and Treatment.

[32]  L. Pusztai,et al.  Gene expression profiling in breast cancer: classification, prognostication, and prediction , 2011, The Lancet.

[33]  S. A. Nair,et al.  Drug-induced Senescence Generates Chemoresistant Stemlike Cells with Low Reactive Oxygen Species* , 2011, The Journal of Biological Chemistry.

[34]  M. Pillai,et al.  The stem cell code in oral epithelial tumorigenesis: 'the cancer stem cell shift hypothesis'. , 2010, Biochimica et biophysica acta.

[35]  D. Yee,et al.  MicroRNAs Link Estrogen Receptor Alpha Status and Dicer Levels in Breast Cancer , 2010, Hormones & cancer.

[36]  C. Clarke,et al.  Progesterone induces adult mammary stem cell expansion , 2010, Nature.

[37]  Anthony Rhodes,et al.  American Society of Clinical Oncology/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. , 2010, Archives of pathology & laboratory medicine.

[38]  Nicholas T. Ingolia,et al.  Mammalian microRNAs predominantly act to decrease target mRNA levels , 2010, Nature.

[39]  Michael J Kerin,et al.  Circulating microRNAs as Novel Minimally Invasive Biomarkers for Breast Cancer , 2010, Annals of surgery.

[40]  P. Pelicci,et al.  Biological and Molecular Heterogeneity of Breast Cancers Correlates with Their Cancer Stem Cell Content , 2010, Cell.

[41]  J. Yun,et al.  MicroRNA‐195 suppresses tumorigenicity and regulates G1/S transition of human hepatocellular carcinoma cells , 2009, Hepatology.

[42]  T. Taguchi,et al.  Association of Breast Cancer Stem Cells Identified by Aldehyde Dehydrogenase 1 Expression with Resistance to Sequential Paclitaxel and Epirubicin-Based Chemotherapy for Breast Cancers , 2009, Clinical Cancer Research.

[43]  A. Onitilo,et al.  Breast Cancer Subtypes Based on ER/PR and Her2 Expression: Comparison of Clinicopathologic Features and Survival , 2009, Clinical Medicine & Research.

[44]  Max S Wicha,et al.  Implications of the cancer stem-cell hypothesis for breast cancer prevention and therapy. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[45]  Max S Wicha,et al.  Cancer stem cells: an old idea--a paradigm shift. , 2006, Cancer research.

[46]  R. Schneider-Broussard,et al.  Side population is enriched in tumorigenic, stem-like cancer cells, whereas ABCG2+ and ABCG2- cancer cells are similarly tumorigenic. , 2005, Cancer research.

[47]  Danila Coradini,et al.  Isolation and in vitro propagation of tumorigenic breast cancer cells with stem/progenitor cell properties. , 2005, Cancer research.

[48]  S. McKinney-Freeman,et al.  Isolation and characterization of side population cells. , 2005, Methods in molecular biology.

[49]  M. Goodell,et al.  A distinct "side population" of cells with high drug efflux capacity in human tumor cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[50]  D. Bartel.  MicroRNAs Genomics, Biogenesis, Mechanism, and Function , 2004, Cell.

[51]  S. Morrison,et al.  Prospective identification of tumorigenic breast cancer cells , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[52]  Carsten O. Peterson,et al.  Estrogen receptor status in breast cancer is associated with remarkably distinct gene expression patterns. , 2001, Cancer research.

[53]  G. Smith,et al.  An entire functional mammary gland may comprise the progeny from a single cell. , 1998, Development.

[54]  J. Spona,et al.  Immunohistochemical and Biochemical Measurement of Estrogen and Progesterone Receptors in Primary Breast Cancer Correlation of Histopathology and Prognostic Factors , 1993, Annals of surgery.